Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multicenter, Randomized, Open Label, Active Controlled, Clinical Study to Assess the Immunogenicity and Safety of Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Manufactured by Serum Institute of India Pvt. Ltd (SIIPL) in Comparison with Boostrix Vaccine of GSK in Healthy Adults, Adolescents and Children in India

Trial Profile

A Phase II/III, Multicenter, Randomized, Open Label, Active Controlled, Clinical Study to Assess the Immunogenicity and Safety of Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Manufactured by Serum Institute of India Pvt. Ltd (SIIPL) in Comparison with Boostrix Vaccine of GSK in Healthy Adults, Adolescents and Children in India

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 13 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top